Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Leukemia

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 403 articles:
HTML format
Text format



Single Articles


    August 2019
  1. CORTES J, Huynh L, Mendelson E, Brandt P, et al
    Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study.
    Leuk Lymphoma. 2019 Aug 13:1-10. doi: 10.1080/10428194.2019.1644332.
    PubMed     Text format     Abstract available


  2. WONG E, Davis J, Koldej R, Szer J, et al
    Nivolumab induces dynamic alterations in CD8 T-cell function and TIM-3 expression when used to treat relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2019 Aug 7:1-4. doi: 10.1080/10428194.2019.1648803.
    PubMed     Text format    


  3. RATAJCZAK B, Gniot M, Przybylowicz-Chalecka A, Czerwinska-Rybak J, et al
    Characterization and significance of the Philadelphia negative/BCR-ABL1 positive rearrangement or masked Philadelphia translocation in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single-center study.
    Leuk Lymphoma. 2019 Aug 7:1-5. doi: 10.1080/10428194.2019.1648807.
    PubMed     Text format    


  4. PRIETO-CONDE MI, Labrador J, Hermida G, Alonso S, et al
    Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder.
    Leuk Lymphoma. 2019 Aug 6:1-4. doi: 10.1080/10428194.2019.1648801.
    PubMed     Text format    


    July 2019
  5. GU JX, Zhang N, Li SS, Zhang AM, et al
    The detection of bacterial infections in leukemia patients using procalcitionin levels.
    Leuk Lymphoma. 2019 Jul 27:1-6. doi: 10.1080/10428194.2019.1646906.
    PubMed     Text format     Abstract available


  6. ANDRITSOS LA, Byrd JC, Cheverton P, Wu J, et al
    A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2019 Jul 27:1-9. doi: 10.1080/10428194.2019.1643463.
    PubMed     Text format     Abstract available


  7. PAIGE E, Thursky K, Slavin M
    Mold-active prophylaxis in acute leukemia: not enough of a good thing?()
    Leuk Lymphoma. 2019 Jul 23:1-3. doi: 10.1080/10428194.2019.1641804.
    PubMed     Text format    


  8. KNORR DA, Goldberg AD, Stein EM, Tallman MS, et al
    Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics.
    Leuk Lymphoma. 2019 Jul 23:1-13. doi: 10.1080/10428194.2019.1639167.
    PubMed     Text format     Abstract available


  9. DHAKAL P, Kaur J, Gundabolu K, Raj Bhatt V, et al
    Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?
    Leuk Lymphoma. 2019 Jul 18:1-11. doi: 10.1080/10428194.2019.1641802.
    PubMed     Text format     Abstract available


  10. CHEN Z, Mai W, Li Z, Zhang H, et al
    The epidemiological trend of acute promyelocytic leukemia over past four decades: a population-based analysis.
    Leuk Lymphoma. 2019 Jul 15:1-12. doi: 10.1080/10428194.2019.1639164.
    PubMed     Text format     Abstract available


  11. ALFAYEZ M, Burger JA, Kadia T, Xu TH, et al
    Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2019 Jul 15:1-2. doi: 10.1080/10428194.2019.1639171.
    PubMed     Text format    


  12. BARRETO JN, Cullen MW, Mara KC, Grove ME, et al
    QT prolongation in patients with acute leukemia or high-risk myelodysplastic syndrome prescribed antifungal prophylaxis during chemotherapy-induced neutropenia.
    Leuk Lymphoma. 2019 Jul 12:1-9. doi: 10.1080/10428194.2019.1639165.
    PubMed     Text format     Abstract available


  13. BASSAN R, Fumagalli M, Chiaretti S, Audisio E, et al
    Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol.
    Leuk Lymphoma. 2019 Jul 12:1-11. doi: 10.1080/10428194.2019.1639170.
    PubMed     Text format     Abstract available


  14. AUTORE F, Sora F, Chiusolo P, Annunziata M, et al
    'Secondary chronic myeloid leukemia': comparison between patients previously exposed or not to chemo- and/or radiotherapy.
    Leuk Lymphoma. 2019 Jul 11:1-3. doi: 10.1080/10428194.2019.1639162.
    PubMed     Text format    


  15. HICKEY E, Clemons B, Griffin S, Cox J, et al
    Multicenter evaluation of arsenic trioxide dosing in obese patients with low-intermediate risk acute promyelocytic leukemia.
    Leuk Lymphoma. 2019 Jul 11:1-4. doi: 10.1080/10428194.2019.1639163.
    PubMed     Text format    


  16. HARADA K, Tachibana T, Ohashi K, Ozawa Y, et al
    The effect of melphalan dose and total body irradiation as reduced-intensity conditioning for acute lymphoblastic leukemia patients undergoing allogeneic stem cell transplantation.
    Leuk Lymphoma. 2019 Jul 10:1-8. doi: 10.1080/10428194.2019.1636986.
    PubMed     Text format     Abstract available


  17. SHENG G, Xue M, Wang Q, Wen L, et al
    Occurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments.
    Leuk Lymphoma. 2019 Jul 8:1-9. doi: 10.1080/10428194.2019.1636984.
    PubMed     Text format     Abstract available


  18. MUESKE NM, Mittelman SD, Wren TAL, Gilsanz V, et al
    Myosteatosis in adolescents and young adults treated for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Jul 2:1-8. doi: 10.1080/10428194.2019.1623889.
    PubMed     Text format     Abstract available


  19. CHOE HK, van Besien K
    Donor graft genotypes versus leukemia.
    Leuk Lymphoma. 2019;60:1606-1607.
    PubMed     Text format    


  20. XUE M, Wang Q, Huo L, Wen L, et al
    Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.
    Leuk Lymphoma. 2019 Jul 1:1-7. doi: 10.1080/10428194.2019.1607329.
    PubMed     Text format     Abstract available


  21. MEHER-HOMJI Z, Tam CS, Siderov J, Seymour JF, et al
    High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribing.
    Leuk Lymphoma. 2019 Jul 1:1-6. doi: 10.1080/10428194.2019.1633640.
    PubMed     Text format     Abstract available


  22. WANG F, Chen Y, Jiang N, Gong S, et al
    Acquired persistently complete remission by decitabine-based treatment for acute myeloid leukemia with the MLL-SEPT9 fusion gene.
    Leuk Lymphoma. 2019 Jul 1:1-4. doi: 10.1080/10428194.2019.1625044.
    PubMed     Text format    


    June 2019
  23. ISHDORJ G, Beiggi S, Nugent Z, Streu E, et al
    Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival.
    Leuk Lymphoma. 2019 Jun 25:1-10. doi: 10.1080/10428194.2019.1620941.
    PubMed     Text format     Abstract available


  24. TATE C, Burgess M, McMillan NA, Saunders NA, et al
    High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy.
    Leuk Lymphoma. 2019 Jun 25:1-5. doi: 10.1080/10428194.2019.1581936.
    PubMed     Text format    


  25. ROSSOFF J, Platanias LC
    Impact of myosteatosis in survivors of childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Jun 21:1-2. doi: 10.1080/10428194.2019.1630623.
    PubMed     Text format    


  26. SHAHRABI S, Maleknia M, Tavakolifar Y, D Zayeri Z, et al
    Neutropenia and leukemia development: genetic risk factors and prognosis.
    Leuk Lymphoma. 2019 Jun 19:1-12. doi: 10.1080/10428194.2019.1630622.
    PubMed     Text format     Abstract available


  27. STAHL M, Tallman MS
    Antibody-based therapy in acute leukemia - beware the risks.
    Leuk Lymphoma. 2019 Jun 17:1-2. doi: 10.1080/10428194.2019.1608535.
    PubMed     Text format    


  28. ACUNA-VILLAORDUNA A, Gonzalez-Lugo J, Ye BH, Adrianzen Herrera DA, et al
    High prevalence of pulmonary findings in computed tomographies of HTLV-1-infected patients with and without adult-T cell leukemia/lymphoma - implications for staging.
    Leuk Lymphoma. 2019 Jun 17:1-5. doi: 10.1080/10428194.2019.1627543.
    PubMed     Text format     Abstract available


  29. ASTORGUES-XERRI L, Vazquez R, Odore E, Rezai K, et al
    Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.
    Leuk Lymphoma. 2019 Jun 17:1-4. doi: 10.1080/10428194.2019.1617860.
    PubMed     Text format    


  30. KIM B, Lee H, Kim E, Shin S, et al
    Clinical utility of targeted NGS panel with comprehensive bioinformatics analysis for patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Jun 17:1-8. doi: 10.1080/10428194.2019.1627538.
    PubMed     Text format     Abstract available


  31. XU D, Claudiani S, Naresh K, Mucklow S, et al
    Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1.
    Leuk Lymphoma. 2019 Jun 11:1-2. doi: 10.1080/10428194.2019.1622101.
    PubMed     Text format    


  32. VASSEUR L, Lara D, Clappier E, Gillebert Q, et al
    Common clonal origin of an EBV-positive diffuse large B cell lymphoma and a chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2019 Jun 11:1-3. doi: 10.1080/10428194.2019.1627539.
    PubMed     Text format    


  33. ELMAAGACLI AH, Salwender H, Jehn C, Dahmash F, et al
    Strong expression of SLAMF7 in natural killer/T-cell lymphoma and large granular lymphocyte leukemia - a prominent biomarker and potential target for anti-SLAMF7 antibody therapy.
    Leuk Lymphoma. 2019 Jun 4:1-4. doi: 10.1080/10428194.2019.1623887.
    PubMed     Text format    


  34. IBRAHIM M, Mendis N, Roma A, Jayanth P, et al
    Anti-leukemia effect of vitamin K3 is mediated through mitochondrial complexes I and II.
    Leuk Lymphoma. 2019 Jun 4:1-4. doi: 10.1080/10428194.2019.1620940.
    PubMed     Text format    


  35. CHEN LS, Keating MJ, Wierda WG, Gandhi V, et al
    Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells.
    Leuk Lymphoma. 2019 Jun 4:1-4. doi: 10.1080/10428194.2019.1622098.
    PubMed     Text format    


  36. DRAGANI M, Rege-Cambrin G, Ferrero D, Abruzzese E, et al
    Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.
    Leuk Lymphoma. 2019 Jun 4:1-3. doi: 10.1080/10428194.2019.1622103.
    PubMed     Text format    


  37. CERRANO M, Candoni A, Crisa E, Dubbini MV, et al
    FLAI induction regimen in elderly patients with acute myeloid leukemia.
    Leuk Lymphoma. 2019 Jun 4:1-2. doi: 10.1080/10428194.2019.1620943.
    PubMed     Text format    


  38. KIMURA K, Tsukamoto S, Takaishi K, Isshiki Y, et al
    T315I mutation with lymphoblasts in a newly diagnosed patient with chronic-phase chronic myeloid leukemia.
    Leuk Lymphoma. 2019;60:1591-1594.
    PubMed     Text format    


    May 2019
  39. ZAJAC-SPYCHALA O, Skalska-Sadowska J, Wachowiak J, Szmydki-Baran A, et al
    Infections in children with acute myeloid leukemia: increased mortality in relapsed/refractory patients.
    Leuk Lymphoma. 2019 May 28:1-8. doi: 10.1080/10428194.2019.1616185.
    PubMed     Text format     Abstract available


  40. BODDU P, Jain P, Borthakur G, Verstovsek S, et al
    Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy.
    Leuk Lymphoma. 2019 May 24:1-9. doi: 10.1080/10428194.2019.1617862.
    PubMed     Text format     Abstract available


  41. KLOOS RQH, Pieters R, van den Bos C, van Eijkelenburg NKA, et al
    The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 May 23:1-9. doi: 10.1080/10428194.2019.1613537.
    PubMed     Text format     Abstract available


  42. CATTANEO C, Gramegna D, Malagola M, Pagani C, et al
    Invasive pulmonary aspergillosis in acute leukemia: a still frequent condition with a negative impact on the overall treatment outcome.
    Leuk Lymphoma. 2019 May 23:1-7. doi: 10.1080/10428194.2019.1613535.
    PubMed     Text format     Abstract available


  43. JOSEPH R, McRee AJ, Mathews S, Zeidner JF, et al
    Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET).
    Leuk Lymphoma. 2019 May 23:1-5. doi: 10.1080/10428194.2019.1612060.
    PubMed     Text format    


  44. BEST S, Liu T, Bruss N, Kittai A, et al
    Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
    Leuk Lymphoma. 2019 May 21:1-5. doi: 10.1080/10428194.2019.1616190.
    PubMed     Text format     Abstract available


  45. TORMO M, Gimenez E, Calabuig M, Talaya A, et al
    Cytomegalovirus DNAemia in patients with de novo acute myeloid leukemia undergoing cytotoxic chemotherapy.
    Leuk Lymphoma. 2019 May 21:1-3. doi: 10.1080/10428194.2019.1613541.
    PubMed     Text format    


  46. PUN CC, Lee KK, Chui YL
    C-terminal BRE inhibits cellular proliferation and increases sensitivity to chemotherapeutic drugs of MLL-AF9 acute myeloid leukemia cells.
    Leuk Lymphoma. 2019 May 21:1-9. doi: 10.1080/10428194.2019.1616184.
    PubMed     Text format     Abstract available


  47. DURAND M, Lacaria K, Sidsworth M, Davis MK, et al
    Management of cardiovascular health in acute leukemia: a national survey.
    Leuk Lymphoma. 2019 May 21:1-11. doi: 10.1080/10428194.2019.1613539.
    PubMed     Text format     Abstract available


  48. INNOCENTI I, Morelli F, Autore F, Tomasso A, et al
    Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
    Leuk Lymphoma. 2019 May 20:1-3. doi: 10.1080/10428194.2019.1612063.
    PubMed     Text format    


  49. SHIMAZU Y, Nohgawa M
    Plasma exchange following mogamulizumab therapy before bone marrow transplantation in refractory adult T-cell leukemia-lymphoma.
    Leuk Lymphoma. 2019 May 20:1-2. doi: 10.1080/10428194.2019.1616188.
    PubMed     Text format    


  50. PAIGE E, Haywood P, Xie M, Worth L, et al
    Auditing fungal disease in leukemia patients in a tertiary care center: opportunities and challenges for an antifungal stewardship program.
    Leuk Lymphoma. 2019 May 17:1-11. doi: 10.1080/10428194.2019.1590570.
    PubMed     Text format     Abstract available


  51. RAFEI H, Kantarjian HM, Jabbour EJ
    Recent advances in the treatment of acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 May 16:1-16. doi: 10.1080/10428194.2019.1605071.
    PubMed     Text format     Abstract available


  52. SOUMERAI JD, Davids MS, Werner L, Fisher DC, et al
    Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2019 May 10:1-8. doi: 10.1080/10428194.2019.1608533.
    PubMed     Text format     Abstract available


  53. SALAMERO O, Martinez-Cuadron D, Sobas M, Benavente C, et al
    Real life outcomes of patients aged >/=75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.
    Leuk Lymphoma. 2019 May 9:1-13. doi: 10.1080/10428194.2019.1607327.
    PubMed     Text format     Abstract available


  54. KREITMAN RJ
    Hairy cell leukemia: present and future directions.
    Leuk Lymphoma. 2019 May 9:1-11. doi: 10.1080/10428194.2019.1608536.
    PubMed     Text format     Abstract available


  55. TAKEDA R, Yokoyama K, Ogawa M, Kawamata T, et al
    The first case of elderly TCF3-HLF-positive B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 May 6:1-4. doi: 10.1080/10428194.2019.1602267.
    PubMed     Text format    


  56. ZHANG X, Guo X
    Coexistence of BCR/ABL1 p190 transcript and CEBPA double mutations in de novo acute myeloid leukemia.
    Leuk Lymphoma. 2019 May 3:1-3. doi: 10.1080/10428194.2019.1608532.
    PubMed     Text format    


  57. DELLA STARZA I, De Novi LA, Santoro A, Salemi D, et al
    Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 May 3:1-3. doi: 10.1080/10428194.2019.1607325.
    PubMed     Text format    


  58. REFAEI M, Radhwi O, Sandhu I, Brandwein J, et al
    A strategy of Day14 bone marrows and early intervention is not superior to a strategy of noDay14 bone marrows and delayed intervention in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2019 May 2:1-9. doi: 10.1080/10428194.2018.1543878.
    PubMed     Text format     Abstract available


    April 2019
  59. ZHANG X, Huang X, Xu H, Li J, et al
    MLL-rearrangement can resemble acute promyelocytic leukemia.
    Leuk Lymphoma. 2019 Apr 30:1-3. doi: 10.1080/10428194.2019.1607328.
    PubMed     Text format    


  60. GABELLI M, Disaro S, Scarparo P, Francescato S, et al
    Cerebrospinal fluid analysis by 8-color flow cytometry in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Apr 25:1-4. doi: 10.1080/10428194.2019.1602269.
    PubMed     Text format    


  61. XIE W, Chen Z, Wang SA, Hu S, et al
    Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
    Leuk Lymphoma. 2019 Apr 24:1-9. doi: 10.1080/10428194.2019.1605509.
    PubMed     Text format     Abstract available


  62. BEZERRA ED, Flowers ME, Onstad LE, Chielens D, et al
    A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2019 Apr 24:1-8. doi: 10.1080/10428194.2019.1605508.
    PubMed     Text format     Abstract available


  63. HAMPEL PJ, Ding W, Call TG, Rabe KG, et al
    Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.
    Leuk Lymphoma. 2019 Apr 24:1-8. doi: 10.1080/10428194.2019.1602268.
    PubMed     Text format     Abstract available


  64. ALDOSS I, Pullarkat V
    Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with NUP214-ABL1.
    Leuk Lymphoma. 2019 Apr 24:1-3. doi: 10.1080/10428194.2019.1605510.
    PubMed     Text format    


  65. TALLIS E, Loghavi S, Jorgensen JL, Wang S, et al
    Patient with mixed-phenotype acute leukemia with CBFB rearrangement.
    Leuk Lymphoma. 2019 Apr 23:1-3. doi: 10.1080/10428194.2019.1605069.
    PubMed     Text format    


  66. TOTH LN, Green D, Peterson J, Deharvengt SJ, et al
    Variant allele frequencies do not correlate well with myeloblast counts in a clinically validated gene sequencing panel for routine acute myeloid leukemia workup.
    Leuk Lymphoma. 2019 Apr 18:1-8. doi: 10.1080/10428194.2019.1587757.
    PubMed     Text format     Abstract available


  67. GOMEZ-ARTEAGA A, Margolskee E, Wei MT, van Besien K, et al
    Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
    Leuk Lymphoma. 2019 Apr 18:1-6. doi: 10.1080/10428194.2019.1594220.
    PubMed     Text format    


  68. FRAISON JB, Grignano E, Braun T, Ades L, et al
    Autoantibodies in myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2019 Apr 8:1-3. doi: 10.1080/10428194.2019.1599114.
    PubMed     Text format    


  69. XU M, Liu H, Liu Y, Ma X, et al
    Gene mutations and pretransplant minimal residual disease predict risk of relapse in adult patients after allogeneic hematopoietic stem-cell transplantation for T cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Apr 5:1-10. doi: 10.1080/10428194.2019.1597270.
    PubMed     Text format     Abstract available


  70. TSIROGIANNI M, Grigoriou E, Kapsimalli V, Dagla K, et al
    Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine.
    Leuk Lymphoma. 2019 Apr 5:1-7. doi: 10.1080/10428194.2019.1581935.
    PubMed     Text format     Abstract available


  71. DOMBRET H, Topp MS, Schuh AC, Wei AH, et al
    Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Apr 5:1-9. doi: 10.1080/10428194.2019.1576872.
    PubMed     Text format     Abstract available


  72. BEYAR-KATZ O, Lavi N, Ringelstein-Harlev S, Henig I, et al
    Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.
    Leuk Lymphoma. 2019 Apr 3:1-8. doi: 10.1080/10428194.2019.1594214.
    PubMed     Text format     Abstract available


    March 2019
  73. DESHIELDS TL, Dueck AC, Rogers K, Brown JR, et al
    Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance).
    Leuk Lymphoma. 2019 Mar 27:1-4. doi: 10.1080/10428194.2019.1594218.
    PubMed     Text format    


  74. BERDEJA JG, Heinrich MC, Dakhil SR, Goldberg SL, et al
    Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.
    Leuk Lymphoma. 2019 Mar 26:1-10. doi: 10.1080/10428194.2019.1590569.
    PubMed     Text format     Abstract available


  75. BUCKLEY SA, Mark NM, Othus M, Estey EH, et al
    Diagnostic utility of bronchoscopy in adults with acute myeloid leukemia and other high-grade myeloid neoplasms.
    Leuk Lymphoma. 2019 Mar 11:1-4. doi: 10.1080/10428194.2019.1581933.
    PubMed     Text format    


  76. NAYMAGON L, Moshier E, Tremblay D, Mascarenhas J, et al
    Predictors of early hemorrhage in acute promyelocytic leukemia.
    Leuk Lymphoma. 2019 Mar 8:1-10. doi: 10.1080/10428194.2019.1581187.
    PubMed     Text format     Abstract available


    February 2019
  77. SALEHI S, Astle JM, Sadigh S, Lake J, et al
    Myeloid neoplasm with eosinophilia and PCM1-JAK2 associated with acute promyelocytic leukemia with PML-RARA.
    Leuk Lymphoma. 2019 Feb 26:1-5. doi: 10.1080/10428194.2019.1581927.
    PubMed     Text format    


  78. KONUMA T, Kato S, Oiwa-Monna M, Mizusawa M, et al
    Myeloablative single-unit cord blood transplantation overcomes the negative prognostic impact of FLT3-ITD in adult acute myeloid leukemia.
    Leuk Lymphoma. 2019 Feb 18:1-4. doi: 10.1080/10428194.2019.1579325.
    PubMed     Text format    


  79. PELLAND-MARCOTTE MC, Hwee J, Pole JD, Nathan PC, et al
    Incidence of infections after therapy completion in children with acute lymphoblastic leukemia or acute myeloid leukemia: a systematic review of the literature.
    Leuk Lymphoma. 2019 Feb 18:1-11. doi: 10.1080/10428194.2019.1573369.
    PubMed     Text format     Abstract available


  80. JAROSOVA M, Plevova K, Kotaskova J, Doubek M, et al
    The importance of complex karyotype in prognostication and treatment of chronic lymphocytic leukemia (CLL): a comprehensive review of the literature.
    Leuk Lymphoma. 2019 Feb 18:1-8. doi: 10.1080/10428194.2019.1576038.
    PubMed     Text format     Abstract available


  81. LAI TH, Mitchell S, Wu PJ, Orwick S, et al
    HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics.
    Leuk Lymphoma. 2019 Feb 18:1-4. doi: 10.1080/10428194.2019.1571197.
    PubMed     Text format    


  82. PEROL L, Grignano E, Contejean A, Gastaud L, et al
    High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors.
    Leuk Lymphoma. 2019 Feb 18:1-4. doi: 10.1080/10428194.2019.1577414.
    PubMed     Text format    


  83. DENG DX, Zhu HH, Liu YR, Chang YJ, et al
    Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
    Leuk Lymphoma. 2019 Feb 18:1-9. doi: 10.1080/10428194.2019.1576868.
    PubMed     Text format     Abstract available


  84. DAI K, Zhang Q, Li Y, Wu L, et al
    Plasma fibrinogen levels correlate with prognosis and treatment outcome in patients with non-M3 acute myeloid leukemia.
    Leuk Lymphoma. 2019 Feb 8:1-9. doi: 10.1080/10428194.2018.1535116.
    PubMed     Text format     Abstract available


  85. WINESTONE LE, Getz KD, Rao P, Li Y, et al
    Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment.
    Leuk Lymphoma. 2019 Feb 7:1-9. doi: 10.1080/10428194.2019.1574002.
    PubMed     Text format     Abstract available


  86. BOSE P, Chen LS, Gandhi V
    Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'.
    Leuk Lymphoma. 2019 Feb 6:1-3. doi: 10.1080/10428194.2019.1571207.
    PubMed     Text format    


  87. XU Y, Zhou X, Li Y, Zhang Y, et al
    Suppression of minichromosome maintenance 7 expression sensitizes chronic lymphocytic leukemia cells to fludarabine.
    Leuk Lymphoma. 2019 Feb 4:1-9. doi: 10.1080/10428194.2018.1523400.
    PubMed     Text format     Abstract available


  88. ZHANG J, Yang F, Qiu HY, Wu Q, et al
    Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Leuk Lymphoma. 2019 Feb 4:1-8. doi: 10.1080/10428194.2018.1533127.
    PubMed     Text format     Abstract available


  89. NATARAJAN H
    Plasma imatinib trough level measurements is still appropriate to predict therapeutic responses in patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2019 Feb 4:1-2. doi: 10.1080/10428194.2019.1571206.
    PubMed     Text format    


  90. ESKAZAN AE
    Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?
    Leuk Lymphoma. 2019 Feb 4:1-2. doi: 10.1080/10428194.2019.1571202.
    PubMed     Text format    


    January 2019
  91. ARGYROU C, Hatziagapiou K, Theodorakidou M, Nikola OA, et al
    The role of adiponectin, LEPTIN, and ghrelin in the progress and prognosis of childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Jan 30:1-12. doi: 10.1080/10428194.2019.1569230.
    PubMed     Text format     Abstract available


  92. RITCHIE EK, Latremouille-Viau D, Guerin A, Pivneva I, et al
    Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective.
    Leuk Lymphoma. 2019 Jan 22:1-9. doi: 10.1080/10428194.2018.1538510.
    PubMed     Text format     Abstract available


  93. KHOT A
    Where do we currently stand with T-cell prolymphocytic leukemia?
    Leuk Lymphoma. 2019 Jan 22:1-3. doi: 10.1080/10428194.2018.1551543.
    PubMed     Text format    


  94. SHIPOUNOVA IN, Petinati NA, Bigildeev AE, Sorokina TV, et al
    Alterations in multipotent mesenchymal stromal cells from the bone marrow of acute myeloid leukemia patients at diagnosis and during treatment.
    Leuk Lymphoma. 2019 Jan 22:1-8. doi: 10.1080/10428194.2018.1554861.
    PubMed     Text format     Abstract available


  95. ECTOR GICG, Govers TM, Westerweel PE, Grutters JPC, et al
    The potential health gain and cost savings of improving adherence in chronic myeloid leukemia.
    Leuk Lymphoma. 2019 Jan 22:1-8. doi: 10.1080/10428194.2018.1535113.
    PubMed     Text format     Abstract available


  96. BEWERSDORF JP, Stahl M, Zeidan AM
    Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
    Leuk Lymphoma. 2019 Jan 17:1-16. doi: 10.1080/10428194.2018.1546854.
    PubMed     Text format     Abstract available


  97. KERMEZLI Y, Saadi W, Belhocine M, Mathieu EL, et al
    A comprehensive catalog of LncRNAs expressed in T-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Jan 16:1-13. doi: 10.1080/10428194.2018.1551534.
    PubMed     Text format     Abstract available


  98. SHEN Y, Crassini K, Sandhu S, Fatima N, et al
    Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment.
    Leuk Lymphoma. 2019 Jan 16:1-12. doi: 10.1080/10428194.2018.1542148.
    PubMed     Text format     Abstract available


  99. QUINTAS-CARDAMA A
    CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond.
    Leuk Lymphoma. 2019 Jan 16:1-3. doi: 10.1080/10428194.2018.1533132.
    PubMed     Text format    


  100. AWAN FT, Thirman MJ, Patel-Donnelly D, Assouline S, et al
    Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
    Leuk Lymphoma. 2019 Jan 11:1-6. doi: 10.1080/10428194.2018.1562180.
    PubMed     Text format     Abstract available


  101. ZHANG X, Li F, Wang J, Suo S, et al
    RARgamma-rearrangements resemble acute promyelocytic leukemia and benefit from 3 + 7 regimen.
    Leuk Lymphoma. 2019 Jan 11:1-4. doi: 10.1080/10428194.2018.1553302.
    PubMed     Text format    


  102. ALBERTSEN BK, Harila-Saari A, Jahnukainen K, Lahteenmaki P, et al
    Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
    Leuk Lymphoma. 2019 Jan 11:1-7. doi: 10.1080/10428194.2018.1538507.
    PubMed     Text format     Abstract available


  103. LASICA M, Willcox A, Burbury K, Ross DM, et al
    The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia.
    Leuk Lymphoma. 2019 Jan 11:1-7. doi: 10.1080/10428194.2018.1551533.
    PubMed     Text format     Abstract available


  104. BODDU P, Gibbons J, Burger J, Sivina M, et al
    Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases.
    Leuk Lymphoma. 2019 Jan 11:1-4. doi: 10.1080/10428194.2018.1547902.
    PubMed     Text format    


  105. TEH BW, Chui W, Handunnetti S, Tam C, et al
    High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2019 Jan 11:1-4. doi: 10.1080/10428194.2018.1543884.
    PubMed     Text format    


  106. SADIGH S, Morrissette JJD, Bagg A
    FBXW7 mutations in acute myeloid leukemia.
    Leuk Lymphoma. 2019 Jan 11:1-2. doi: 10.1080/10428194.2018.1537488.
    PubMed     Text format    


  107. DANESE MD, Katz A, Cetin K, Chia V, et al
    Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data.
    Leuk Lymphoma. 2019 Jan 11:1-10. doi: 10.1080/10428194.2018.1555329.
    PubMed     Text format     Abstract available


  108. ESTEY E
    'Looking beyond survival to define therapeutic value in acute myeloid leukemia'.
    Leuk Lymphoma. 2019 Jan 10:1-3. doi: 10.1080/10428194.2018.1543886.
    PubMed     Text format    


  109. MA H, Padmanabhan Iyer S, Parmar S, Gong Y, et al
    Adoptive cell therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2019 Jan 10:1-11. doi: 10.1080/10428194.2018.1553300.
    PubMed     Text format     Abstract available


  110. SCHORE RJ, Devidas M, Bleyer A, Reaman GH, et al
    Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4().
    Leuk Lymphoma. 2019 Jan 10:1-9. doi: 10.1080/10428194.2018.1542146.
    PubMed     Text format     Abstract available


  111. WANG Q, Wan J, Zhang W, Hao S, et al
    MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells.
    Leuk Lymphoma. 2019 Jan 10:1-11. doi: 10.1080/10428194.2018.1563694.
    PubMed     Text format     Abstract available


  112. CHAOUI D, Hacini M, Fitoussi O, Karlin L, et al
    Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.
    Leuk Lymphoma. 2019 Jan 9:1-5. doi: 10.1080/10428194.2018.1533130.
    PubMed     Text format    


  113. FOURNIER E, Inchiappa L, Delattre C, Pignon JM, et al
    Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature.
    Leuk Lymphoma. 2019 Jan 7:1-4. doi: 10.1080/10428194.2018.1562185.
    PubMed     Text format    


  114. AKHTAR OS, Attwood K, Lund I, Hare R, et al
    Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2019 Jan 2:1-6. doi: 10.1080/10428194.2018.1554862.
    PubMed     Text format     Abstract available


  115. KNORR KLB, Tallman MS
    LeukeMYC prognostication.
    Leuk Lymphoma. 2019;60:1-2.
    PubMed     Text format    


    December 2018
  116. AUTORE F, Chiusolo P, Sora F, Giammarco S, et al
    Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid.
    Leuk Lymphoma. 2018 Dec 11:1-3. doi: 10.1080/10428194.2018.1522436.
    PubMed     Text format    


  117. LABRADOR J, Luno E, Vellenga E, Brunet S, et al
    Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Leuk Lymphoma. 2018 Dec 11:1-10. doi: 10.1080/10428194.2018.1522438.
    PubMed     Text format     Abstract available


  118. YAMAMOTO K, Yakushijin K, Ichikawa H, Okamura A, et al
    Coexpression of ETV6/MDS1/EVI1 and ETV6/EVI1 fusion transcripts in acute myeloid leukemia with t(3;12)(q26.2;p13) and thrombocytosis.
    Leuk Lymphoma. 2018 Dec 11:1-5. doi: 10.1080/10428194.2018.1529311.
    PubMed     Text format    


  119. MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
    The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis.
    Leuk Lymphoma. 2018 Dec 5:1-6. doi: 10.1080/10428194.2018.1543882.
    PubMed     Text format     Abstract available


  120. KIM S, Freeland-Graves JH, Babaei M, Sachdev PK, et al
    Quantifying the association between acute leukemia and serum zinc, copper, and selenium: a meta-analysis.
    Leuk Lymphoma. 2018 Dec 5:1-9. doi: 10.1080/10428194.2018.1540043.
    PubMed     Text format     Abstract available


  121. JIANG X, Cheng Y, Hu C, Zhang A, et al
    MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5.
    Leuk Lymphoma. 2018 Dec 5:1-12. doi: 10.1080/10428194.2018.1543875.
    PubMed     Text format     Abstract available


  122. OCK CY, Seo H, Kim DY, Min BJ, et al
    Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia.
    Leuk Lymphoma. 2018 Dec 3:1-7. doi: 10.1080/10428194.2018.1542142.
    PubMed     Text format     Abstract available


  123. MICHAILOV Y, Lunenfeld E, Kapelushnik J, Huleihel M, et al
    Leukemia and male infertility: past, present, and future.
    Leuk Lymphoma. 2018 Dec 3:1-10. doi: 10.1080/10428194.2018.1533126.
    PubMed     Text format     Abstract available


    November 2018
  124. NAMN Y, Furman RR, Crawford C
    A rare colonic manifestation of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Nov 29:1-4. doi: 10.1080/10428194.2018.1459612.
    PubMed     Text format    


  125. SUN Y, Murty VV, Leeman-Neill R, Soderquist C, et al
    Cytogenetic analysis of adult T-Cell leukemia/lymphoma: evaluation of a Caribbean cohort.
    Leuk Lymphoma. 2018 Nov 27:1-3. doi: 10.1080/10428194.2018.1538506.
    PubMed     Text format    


  126. HARADA K, Yanada M, Machida S, Kanamori H, et al
    Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning.
    Leuk Lymphoma. 2018 Nov 20:1-10. doi: 10.1080/10428194.2018.1535115.
    PubMed     Text format     Abstract available


  127. DIAMANTOPOULOS PT, Kotsianidis I, Symeonidis A, Pappa V, et al
    Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.
    Leuk Lymphoma. 2018 Nov 14:1-10. doi: 10.1080/10428194.2018.1540783.
    PubMed     Text format     Abstract available


  128. SOUMERAI JD, Ni A, Xing G, Huang J, et al
    Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
    Leuk Lymphoma. 2018 Nov 8:1-9. doi: 10.1080/10428194.2018.1540782.
    PubMed     Text format     Abstract available


  129. GURU MURTHY GS, Pondaiah SK, Abedin S, Atallah E, et al
    Incidence and survival of T-cell acute lymphoblastic leukemia in the United States.
    Leuk Lymphoma. 2018 Nov 8:1-8. doi: 10.1080/10428194.2018.1522442.
    PubMed     Text format     Abstract available


  130. NABHAN C, Kamat S, Karl Kish J
    Acute myeloid leukemia in the elderly: what constitutes treatment value?
    Leuk Lymphoma. 2018 Nov 8:1-7. doi: 10.1080/10428194.2018.1520992.
    PubMed     Text format     Abstract available


  131. RODRIGUEZ CM, Bussi C, Arroyo DS, Sastre D, et al
    Effects of rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells.
    Leuk Lymphoma. 2018 Nov 8:1-5. doi: 10.1080/10428194.2018.1529309.
    PubMed     Text format    


  132. TAO S, Wang C, Chen Y, Deng Y, et al
    Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia.
    Leuk Lymphoma. 2018 Nov 8:1-9. doi: 10.1080/10428194.2018.1504941.
    PubMed     Text format     Abstract available


  133. ZAJAC-SPYCHALA O, Wachowiak J, Szmydki-Baran A, Hutnik L, et al
    Infectious complications in children treated for hodgkin and non-hodgkin lymphomas in polish pediatric leukemia/lymphoma study group: incidence, epidemiology and etiology.
    Leuk Lymphoma. 2018 Nov 5:1-9. doi: 10.1080/10428194.2018.1466293.
    PubMed     Text format     Abstract available


    October 2018
  134. POPP HD, Flach J, Brendel S, Ruppenthal S, et al
    Accumulation of DNA damage and alteration of the DNA damage response in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Oct 31:1-10. doi: 10.1080/10428194.2018.1498494.
    PubMed     Text format     Abstract available


  135. ZHANG S, Zhou W, Li Y, Yu S, et al
    Co-expression of AML1-ETO and PML-RARa following treatment of de novo acute myeloid leukemia with AML1-ETO.
    Leuk Lymphoma. 2018 Oct 17:1-4. doi: 10.1080/10428194.2018.1520991.
    PubMed     Text format    


  136. CHEN J, Ngo D, Aldoss I, Shayani S, et al
    Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Oct 15:1-6. doi: 10.1080/10428194.2018.1519811.
    PubMed     Text format     Abstract available


  137. BHANGOO MS, Saven A
    Secondary malignancies after treatment with single-agent vemurafenib in two patients with refractory hairy cell leukemia.
    Leuk Lymphoma. 2018 Oct 15:1-3. doi: 10.1080/10428194.2018.1519809.
    PubMed     Text format    


  138. SOBAS M, Montesinos P, Boluda B, Bernal T, et al
    An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.
    Leuk Lymphoma. 2018 Oct 15:1-6. doi: 10.1080/10428194.2018.1516875.
    PubMed     Text format     Abstract available


  139. DAVIDS MS, Kim HT, Yu L, De Maeyer G, et al
    Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Oct 15:1-4. doi: 10.1080/10428194.2018.1519814.
    PubMed     Text format     Abstract available


  140. MEI C, Ren Y, Zhou X, Ye L, et al
    Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study.
    Leuk Lymphoma. 2018 Oct 10:1-10. doi: 10.1080/10428194.2018.1515938.
    PubMed     Text format     Abstract available


  141. MOLICA S, Giannarelli D, Levato L, Mirabelli R, et al
    A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients.
    Leuk Lymphoma. 2018 Oct 2:1-3. doi: 10.1080/10428194.2018.1508674.
    PubMed     Text format    


  142. NIEBOROWSKA-SKORSKA M, Maifrede S, Ye M, Toma M, et al
    Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia.
    Leuk Lymphoma. 2018 Oct 2:1-4. doi: 10.1080/10428194.2018.1520988.
    PubMed     Text format    


  143. CHEN X, Wang F, Zhang Y, Wang M, et al
    Panoramic view of common fusion genes in a large cohort of Chinese de novo acute myeloid leukemia patients.
    Leuk Lymphoma. 2018 Oct 2:1-8. doi: 10.1080/10428194.2018.1516876.
    PubMed     Text format     Abstract available


  144. BUCKLEY SA, Percival ME, Othus M, Halpern AB, et al
    A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.
    Leuk Lymphoma. 2018 Oct 2:1-7. doi: 10.1080/10428194.2018.1516036.
    PubMed     Text format     Abstract available


  145. MILLER KC, Al-Kali A, Shah MV, Hogan WJ, et al
    Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients.
    Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1509318.
    PubMed     Text format     Abstract available


  146. WESTHUS J, Noppeney R, Duhrsen U, Hanoun M, et al
    FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
    Leuk Lymphoma. 2018 Oct 2:1-9. doi: 10.1080/10428194.2018.1508670.
    PubMed     Text format     Abstract available


  147. BARRIENTOS JC, Burger JA, Byrd JC, Hillmen P, et al
    Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
    Leuk Lymphoma. 2018 Oct 2:1-6. doi: 10.1080/10428194.2018.1512710.
    PubMed     Text format     Abstract available


  148. SHETH V, Nachmias B, Grisariu S, Avni B, et al
    Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia - improved outcomes with similar toxicity.
    Leuk Lymphoma. 2018 Oct 2:1-8. doi: 10.1080/10428194.2018.1510495.
    PubMed     Text format     Abstract available


  149. CHEN CI, Paul H, Snitzler S, Kakar S, et al
    A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1508669.
    PubMed     Text format     Abstract available


  150. ROSSOFF J, Akpan I, Platanias LC
    Spontaneous remission in congenital leukemia.
    Leuk Lymphoma. 2018;59:2271-2272.
    PubMed     Text format    


    September 2018
  151. D'ARENA G, Seneca E, Migliaccio I, De Feo V, et al
    Oxidative stress in chronic lymphocytic leukemia: still a matter of debate.
    Leuk Lymphoma. 2018 Sep 20:1-9. doi: 10.1080/10428194.2018.1509317.
    PubMed     Text format     Abstract available


  152. MCMAHON CM, Perl AE
    Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
    Leuk Lymphoma. 2018 Sep 20:1-14. doi: 10.1080/10428194.2018.1504937.
    PubMed     Text format     Abstract available


  153. EREN R, Karismaz A, Karatas D, Dogu MH, et al
    Comparison of clinical features and survival between young and old chronic lymphocytic leukemia patients: a single center study from Turkey.
    Leuk Lymphoma. 2018 Sep 6:1-6. doi: 10.1080/10428194.2018.1509316.
    PubMed     Text format     Abstract available


  154. SAENZ-DE-VITERI M, Cudrnak T
    Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
    Leuk Lymphoma. 2018 Sep 6:1-3. doi: 10.1080/10428194.2018.1508673.
    PubMed     Text format    


  155. FERREIRA LAM, Capannacci J, Hokama NK, Nogueira CR, et al
    Circulating microRNAs expression profile in newly diagnosed and imatinib treated chronic phase - chronic myeloid leukemia.
    Leuk Lymphoma. 2018 Sep 6:1-7. doi: 10.1080/10428194.2018.1499905.
    PubMed     Text format     Abstract available


  156. GIANFELICI V, Messina M, Paoloni F, Peragine N, et al
    IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.
    Leuk Lymphoma. 2018 Sep 6:1-4. doi: 10.1080/10428194.2018.1499906.
    PubMed     Text format    


  157. KNEZ V, Liu X, Schowinsky J, Pan Z, et al
    Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: a multi-institutional study.
    Leuk Lymphoma. 2018 Sep 6:1-8. doi: 10.1080/10428194.2018.1508667.
    PubMed     Text format     Abstract available


  158. HE C, Luo B, Jiang N, Liang Y, et al
    OncomiR or antioncomiR: Role of miRNAs in Acute Myeloid Leukemia.
    Leuk Lymphoma. 2018 Sep 6:1-12. doi: 10.1080/10428194.2018.1480769.
    PubMed     Text format     Abstract available


  159. KUTTIKRISHNAN S, Siveen KS, Prabhu KS, Khan AQ, et al
    Sanguinarine suppresses growth and induces apoptosis in childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Sep 6:1-13. doi: 10.1080/10428194.2018.1494270.
    PubMed     Text format     Abstract available


  160. MAZHARUDDIN S, Chattopadhyay A, Levy MY, Redner RL, et al
    IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid.
    Leuk Lymphoma. 2018;59:2246-2249.
    PubMed     Text format    


  161. LAMBA JK, Voigt AP, Chauhan L, Shin M, et al
    CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients.
    Leuk Lymphoma. 2018;59:2250-2253.
    PubMed     Text format    


  162. KOMMALAPATI A, Kushchayeva Y, Tella SH
    Incidence, racial disparities and survival outcomes of mast cell malignancies: analysis from a national database.
    Leuk Lymphoma. 2018;59:2254-2257.
    PubMed     Text format    


  163. OO ZM, Illendula A, Grembecka J, Schmidt C, et al
    A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFbeta in leukemic cells.
    Leuk Lymphoma. 2018;59:2188-2200.
    PubMed     Text format     Abstract available


    August 2018
  164. BORLENGHI E, Cattaneo C, Schieppati F, Gramegna D, et al
    Acute promyelocytic leukemia in patients aged >70 years is not rare and highly curable: a single center series of 21 unselected patients.
    Leuk Lymphoma. 2018 Aug 30:1-4. doi: 10.1080/10428194.2018.1492126.
    PubMed     Text format    


  165. CAO M, Carrasco RD, Dubuc AM, Dal Cin P, et al
    ZMYM2-FGFR1 fusion as secondary change in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Aug 30:1-3. doi: 10.1080/10428194.2018.1493733.
    PubMed     Text format    


  166. SPEZIALI C, Daly A, Abuhaleeqa M, Nitta J, et al
    Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Aug 30:1-10. doi: 10.1080/10428194.2018.1493734.
    PubMed     Text format     Abstract available


  167. JABBOUR EJ, Siegartel LR, Lin J, Lingohr-Smith M, et al
    Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States.
    Leuk Lymphoma. 2018 Aug 20:1-7. doi: 10.1080/10428194.2018.1492124.
    PubMed     Text format     Abstract available


  168. NATARAJAN H, Kumar L, Bakhshi S, Sharma A, et al
    Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2018 Aug 20:1-8. doi: 10.1080/10428194.2018.1485907.
    PubMed     Text format     Abstract available


  169. OLSHANSKAYA Y, Kazakova A, Tsaur G, Zerkalenkova E, et al
    Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow-Berlin (MB).
    Leuk Lymphoma. 2018 Aug 1:1-7. doi: 10.1080/10428194.2018.1485904.
    PubMed     Text format     Abstract available


  170. WALZ JS, Kowalewski DJ, Backert L, Nelde A, et al
    Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers.
    Leuk Lymphoma. 2018;59:1949-1958.
    PubMed     Text format     Abstract available


  171. MA J, Dunlap J, Paliga A, Traer E, et al
    DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.
    Leuk Lymphoma. 2018;59:1938-1948.
    PubMed     Text format     Abstract available


  172. SHEN Y, Best OG, Mulligan SP, Christopherson RI, et al
    Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.
    Leuk Lymphoma. 2018;59:1927-1937.
    PubMed     Text format     Abstract available


  173. AW A, Kim HT, Fernandes SM, Hoang K, et al
    Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry.
    Leuk Lymphoma. 2018;59:1986-1989.
    PubMed     Text format    


    July 2018
  174. XU YP, Wieten L, Wang SX, Cai Y, et al
    Clinical significance of HLA-E genotype and surface/soluble expression levels between healthy individuals and patients with acute leukemia.
    Leuk Lymphoma. 2018 Jul 3:1-8. doi: 10.1080/10428194.2018.1474521.
    PubMed     Text format     Abstract available


  175. CHELLAPANDIAN D, Pole JD, Nathan PC, Sung L, et al
    Congestive heart failure among children with acute leukemia: a population-based matched cohort study.
    Leuk Lymphoma. 2018 Jul 3:1-10. doi: 10.1080/10428194.2018.1474522.
    PubMed     Text format     Abstract available


  176. KAIFIE A, Schikowsky C, Vasko T, Kraus T, et al
    Additional benefits of telomere length (TL) measurements in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Jul 3:1-3. doi: 10.1080/10428194.2018.1482544.
    PubMed     Text format    


  177. KATHIRAVAN M, Singh M, Bhatia P, Trehan A, et al
    Deletion of CDKN2A/B is associated with inferior relapse free survival in pediatric B cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Jul 3:1-9. doi: 10.1080/10428194.2018.1482542.
    PubMed     Text format     Abstract available


  178. JURCZYSZYN A, Castillo JJ, Avivi I, Czepiel J, et al
    Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.
    Leuk Lymphoma. 2018 Jul 2:1-6. doi: 10.1080/10428194.2018.1473574.
    PubMed     Text format     Abstract available


  179. ERBILGIN Y, Eskazan AE, Hatirnaz Ng O, Salihoglu A, et al
    Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors.
    Leuk Lymphoma. 2018 Jul 2:1-9. doi: 10.1080/10428194.2018.1473573.
    PubMed     Text format     Abstract available


  180. STAHL M, DeVeaux M, Montesinos P, Itzykson R, et al
    Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jul 2:1-4. doi: 10.1080/10428194.2018.1468893.
    PubMed     Text format    


  181. LOZANO C, Brun S, Arnaud A, Gaulard P, et al
    Complete remission of agranulocytosis after splenectomy in a variant form of T-cell large granular lymphocyte leukemia.
    Leuk Lymphoma. 2018 Jul 2:1-4. doi: 10.1080/10428194.2018.1471601.
    PubMed     Text format    


  182. SAGLIO G, Jabbour E
    First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.
    Leuk Lymphoma. 2018;59:1523-1538.
    PubMed     Text format     Abstract available


  183. TANG CPS, McMullen J, Tam C
    Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
    Leuk Lymphoma. 2018;59:1554-1564.
    PubMed     Text format     Abstract available


  184. STRATI P, Tang G, Duose DY, Mallampati S, et al
    Myeloid/lymphoid neoplasms with FGFR1 rearrangement.
    Leuk Lymphoma. 2018;59:1672-1676.
    PubMed     Text format     Abstract available


  185. DASGUPTA Y, Golovine K, Nieborowska-Skorska M, Luo L, et al
    Drugging DNA repair to target T-ALL cells.
    Leuk Lymphoma. 2018;59:1746-1749.
    PubMed     Text format    


  186. BURKE MJ, Devidas M, Maloney K, Angiolillo A, et al
    Severe pegaspargase hypersensitivity reaction rates (grade >/=3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.
    Leuk Lymphoma. 2018;59:1624-1633.
    PubMed     Text format     Abstract available


  187. VAKHARIA P, Nardone B, Budris W, Hoshizaki K, et al
    Blinatumomab and pancreatitis: an analysis of FAERS, EudraVigilance, and a large urban U.S. patient population data.
    Leuk Lymphoma. 2018;59:1759-1761.
    PubMed     Text format    


    June 2018
  188. CAPRIA S, Pepe S, Trisolini SM, Testi AM, et al
    Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease.
    Leuk Lymphoma. 2018 Jun 26:1-3. doi: 10.1080/10428194.2018.1468895.
    PubMed     Text format    


  189. PODSZYWALOW-BARTNICKA P, Maifrede S, Le BV, Nieborowska-Skorska M, et al
    PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions.
    Leuk Lymphoma. 2018 Jun 22:1-3. doi: 10.1080/10428194.2018.1471602.
    PubMed     Text format    


  190. CHEN CI, Paul H, Le LW, Wei EN, et al
    A phase 2 study of ofatumumab (Arzerra((R))) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2018 Jun 19:1-9. doi: 10.1080/10428194.2018.1468892.
    PubMed     Text format     Abstract available


  191. THAN H, Lye WK, Sng C, Allen JC Jr, et al
    BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients.
    Leuk Lymphoma. 2018 Jun 19:1-4. doi: 10.1080/10428194.2018.1461863.
    PubMed     Text format    


  192. CRASSINI K, Pyke T, Shen Y, Stevenson WS, et al
    Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells.
    Leuk Lymphoma. 2018 Jun 18:1-12. doi: 10.1080/10428194.2018.1455974.
    PubMed     Text format     Abstract available


  193. STRATI P, Gabutti C, Thompson PA, Kontoyiannis DP, et al
    Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Jun 18:1-3. doi: 10.1080/10428194.2018.1474527.
    PubMed     Text format    


  194. PAPAGEORGIOU SG, Diamantopoulos MA, Kontos CK, Bouchla A, et al
    MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Jun 18:1-10. doi: 10.1080/10428194.2018.1461861.
    PubMed     Text format     Abstract available


  195. YAMAMOTO K, Yakushijin K, Ichikawa H, Kakiuchi S, et al
    Expression of a novel ZMYND11/MBTD1 fusion transcript in CD7(+)CD56(+) acute myeloid leukemia with t(10;17)(p15;q21).
    Leuk Lymphoma. 2018 Jun 18:1-5. doi: 10.1080/10428194.2018.1464157.
    PubMed     Text format    


  196. BERTOLI S, Tavitian S, Berard E, Gadaud N, et al
    Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies.
    Leuk Lymphoma. 2018 Jun 12:1-4. doi: 10.1080/10428194.2018.1464156.
    PubMed     Text format    


  197. HIWASE D, Ross D
    Success is built on failures: tackling the challenge of ponatinib failure.
    Leuk Lymphoma. 2018;59:1279-1281.
    PubMed     Text format    


  198. BODDU P, Shah AR, Borthakur G, Verstovsek S, et al
    Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.
    Leuk Lymphoma. 2018;59:1312-1322.
    PubMed     Text format     Abstract available


  199. BODDU P, Oviedo SP, Rausch CR, Yam C, et al
    PET-CT in AML-related hemophagocytic lymphohistiocytosis.
    Leuk Lymphoma. 2018;59:1486-1489.
    PubMed     Text format    


    May 2018
  200. PLEYER C, Wiestner A, Sun C
    Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 May 15:1-9. doi: 10.1080/10428194.2018.1457147.
    PubMed     Text format     Abstract available


  201. YOGARAJAH M, Montgomery N, Matson M, Blanchard L, et al
    Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after azacitidine treatment.
    Leuk Lymphoma. 2018 May 11:1-3. doi: 10.1080/10428194.2018.1459614.
    PubMed     Text format    


  202. OHANIAN M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, et al
    MYC protein expression is an important prognostic factor in acute myeloid leukemia.
    Leuk Lymphoma. 2018 May 9:1-12. doi: 10.1080/10428194.2018.1464158.
    PubMed     Text format     Abstract available


  203. KRULL K, Kunstreich M, Bronsema A, Bleckmann K, et al
    Osteonecrosis in children with acute lymphoblastic leukemia at initial diagnosis and prior to any chemotherapy.
    Leuk Lymphoma. 2018 May 2:1-7. doi: 10.1080/10428194.2018.1466292.
    PubMed     Text format     Abstract available


  204. LICATA MJ, Janakiram M, Tan S, Fang Y, et al
    Diagnostic challenges of adult T-cell leukemia/lymphoma in North America - a clinical, histological, and immunophenotypic correlation with a workflow proposal.
    Leuk Lymphoma. 2018;59:1188-1194.
    PubMed     Text format     Abstract available


  205. SATO E, Iriyama N, Tokuhira M, Takaku T, et al
    Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.
    Leuk Lymphoma. 2018;59:1105-1112.
    PubMed     Text format     Abstract available


    April 2018
  206. STAHL M, Pine A, Hendrickson JE, Litzow MR, et al
    Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey().
    Leuk Lymphoma. 2018 Apr 18:1-4. doi: 10.1080/10428194.2018.1452219.
    PubMed     Text format    


  207. TAKEI T, Yokoyama K, Shimizu E, Konuma T, et al
    Azacitidine effectively reduces TP53-mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation.
    Leuk Lymphoma. 2018 Apr 12:1-2. doi: 10.1080/10428194.2018.1443335.
    PubMed     Text format    


  208. REDNER RL, Beumer JH, Kropf P, Agha M, et al
    A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-7. doi: 10.1080/10428194.2018.1443330.
    PubMed     Text format     Abstract available


  209. OJAMIES PN, Kontro M, Edgren H, Ellonen P, et al
    Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1453067.
    PubMed     Text format    


  210. ZHANG H, Liang Z, Hu Y, Wang X, et al
    The effectiveness of interferon-alpha combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.
    Leuk Lymphoma. 2018 Apr 4:1-2. doi: 10.1080/10428194.2018.1443329.
    PubMed     Text format    


  211. VAN DER STRATEN L, Dinmohamed AG, Westerweel PE, Langerak AW, et al
    Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy.
    Leuk Lymphoma. 2018 Apr 4:1-5. doi: 10.1080/10428194.2018.1452215.
    PubMed     Text format    


  212. IMAGAWA J
    Switching from all-trans retinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-3. doi: 10.1080/10428194.2018.1443333.
    PubMed     Text format    


  213. KUROSAWA S, Toya T, Kishida Y, Nagata A, et al
    Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1441410.
    PubMed     Text format    


  214. HUANG J, Hong M, Zhu Y, Zhao H, et al
    Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-10. doi: 10.1080/10428194.2018.1443328.
    PubMed     Text format     Abstract available


  215. BODDU P, Kantarjian H, Garcia-Manero G, Allison J, et al
    The emerging role of immune checkpoint based approaches in AML and MDS.
    Leuk Lymphoma. 2018;59:790-802.
    PubMed     Text format     Abstract available


    March 2018
  216. HOVERSTEN K, Vallapureddy R, Lasho T, Finke C, et al
    Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates.
    Leuk Lymphoma. 2018 Mar 27:1-4. doi: 10.1080/10428194.2018.1452212.
    PubMed     Text format    


  217. MACDONALD RJ, Bunaciu RP, Ip V, Dai D, et al
    Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells.
    Leuk Lymphoma. 2018 Mar 23:1-11. doi: 10.1080/10428194.2018.1452213.
    PubMed     Text format     Abstract available


  218. SORIGUE M, Orna E, Sancho JM
    Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review.
    Leuk Lymphoma. 2018 Mar 21:1-10. doi: 10.1080/10428194.2018.1448085.
    PubMed     Text format     Abstract available


  219. PRESS KR, Uy N, Keefer J, Gore SD, et al
    Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes.
    Leuk Lymphoma. 2018;59:755-757.
    PubMed     Text format    


  220. HIRAI M, Yagasaki H, Fujimura J, Inoue M, et al
    Successful preemptive donor lymphocyte infusions from a haploidentical donor in a boy with E2A-HLF-positive ALL.
    Leuk Lymphoma. 2018;59:746-748.
    PubMed     Text format    


    February 2018
  221. JIANG JG, Xu Y, Wu Z, Ni H, et al
    Acute myeloid leukemia developed in Ph- cells with MLL gene amplification in a patient with chronic myelogenous leukemia.
    Leuk Lymphoma. 2018 Feb 23:1-3. doi: 10.1080/10428194.2018.1436174.
    PubMed     Text format    


  222. DE LUCA G, Trasarti S, Bizzoni L, Del Giudice I, et al
    Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders.
    Leuk Lymphoma. 2018 Feb 23:1-4. doi: 10.1080/10428194.2018.1439583.
    PubMed     Text format    


  223. CASEY N, Fujiwara H, Azuma T, Murakami Y, et al
    An unusual, CD4 and CD8 dual-positive, CD25 negative, tumor cell phenotype in a patient with adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1439168.
    PubMed     Text format    


  224. MOLICA S, Levato L, Mirabelli R, Tedeschi A, et al
    Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1436175.
    PubMed     Text format    


  225. ROZOVSKI U, Harris DM, Li P, Liu Z, et al
    Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Feb 21:1-6. doi: 10.1080/10428194.2018.1439167.
    PubMed     Text format     Abstract available


  226. VAN DE LOUW A, Desai RJ, Zhu J, Claxton DF, et al
    Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-8. doi: 10.1080/10428194.2018.1435874.
    PubMed     Text format     Abstract available


  227. IKAWA Y, Nishimura R, Maeba H, Fujiki T, et al
    Deep spontaneous molecular remission in a patient with congenital acute myeloid leukemia expressing a novel MOZ-p300 fusion transcript.
    Leuk Lymphoma. 2018 Feb 12:1-3. doi: 10.1080/10428194.2018.1434885.
    PubMed     Text format    


  228. KARANTANOU C, Godavarthy PS, Krause DS
    Targeting the bone marrow microenvironment in acute leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-11. doi: 10.1080/10428194.2018.1434886.
    PubMed     Text format     Abstract available


  229. KRUPAR R, Schreiber C, Offermann A, Lengerke C, et al
    In silico analysis of anti-leukemia immune response and immune evasion in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-4. doi: 10.1080/10428194.2018.1434883.
    PubMed     Text format    


  230. SMIRNIKHINA SA, Chelysheva EY, Lavrov AV, Kochergin-Nikitsky KS, et al
    Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation.
    Leuk Lymphoma. 2018 Feb 9:1-4. doi: 10.1080/10428194.2018.1434880.
    PubMed     Text format    


  231. ZAJAC-SPYCHALA O, Pawlak M, Karmelita-Katulska K, Pilarczyk J, et al
    Anti-leukemic treatment-induced neurotoxicity in long-term survivors of childhood acute lymphoblastic leukemia: impact of reduced central nervous system radiotherapy and intermediate- to high-dose methotrexate.
    Leuk Lymphoma. 2018 Feb 9:1-10. doi: 10.1080/10428194.2018.1434879.
    PubMed     Text format     Abstract available


  232. DERRIEUX C, Freynet N, Frayfer J, Delabesse E, et al
    A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia.
    Leuk Lymphoma. 2018 Feb 9:1-4. doi: 10.1080/10428194.2018.1430796.
    PubMed     Text format    


  233. ALVAREZ E, Muffly L, Li Q, Brunson A, et al
    Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California.
    Leuk Lymphoma. 2018 Feb 9:1-3. doi: 10.1080/10428194.2018.1427856.
    PubMed     Text format    


  234. HE F, Sapkota S, Parker S, Defor T, et al
    A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 7:1-8. doi: 10.1080/10428194.2018.1433297.
    PubMed     Text format     Abstract available


  235. FLOWERS CR, Nabhan C, Kay NE, Mato A, et al
    Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect((R)) CLL cohort study.
    Leuk Lymphoma. 2018 Feb 7:1-9. doi: 10.1080/10428194.2018.1427860.
    PubMed     Text format     Abstract available


  236. TORREBADELL M, Diaz-Beya M, Kalko SG, Pratcorona M, et al
    A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 2:1-11. doi: 10.1080/10428194.2017.1422859.
    PubMed     Text format     Abstract available


  237. IMBERT V, Nebout M, Mary D, Endou H, et al
    Co-targeting intracellular pH and essential amino acid uptake cooperates to induce cell death of T-ALL/LL cells.
    Leuk Lymphoma. 2018;59:460-468.
    PubMed     Text format     Abstract available


  238. THORP BC, Badoux X
    Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Leuk Lymphoma. 2018;59:311-320.
    PubMed     Text format     Abstract available


  239. BEZERRA ED, Smith H, Estey E
    A case of indolent AML with five-year survival without treatment.
    Leuk Lymphoma. 2018;59:519.
    PubMed     Text format    


  240. KASHOFER K, Gornicec M, Lind K, Caraffini V, et al
    Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing.
    Leuk Lymphoma. 2018;59:501-504.
    PubMed     Text format    


  241. DANIELZIK T, Koldehoff M, Buttkereit U, Beelen DW, et al
    Sensitive detection of rare antigen-specific T cells directed against Wilms' tumor 1 by FluoroSpot assay.
    Leuk Lymphoma. 2018;59:490-492.
    PubMed     Text format    


  242. LAD D, Hoeppli R, Huang Q, Garcia R, et al
    Regulatory T-cells drive immune dysfunction in CLL.
    Leuk Lymphoma. 2018;59:486-489.
    PubMed     Text format    


    January 2018
  243. SCIUME M, Fracchiolla NS, Cortelezzi A
    Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Jan 31:1-2. doi: 10.1080/10428194.2018.1429603.
    PubMed     Text format    


  244. ZHANG Y, Qu S, Wang Q, Li J, et al
    A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).
    Leuk Lymphoma. 2018 Jan 31:1-3. doi: 10.1080/10428194.2018.1427855.
    PubMed     Text format    


  245. ANDO T, Kojima K, Sano H, Kidoguchi K, et al
    Successful treatment of post-transplant relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide.
    Leuk Lymphoma. 2018 Jan 31:1-4. doi: 10.1080/10428194.2018.1427859.
    PubMed     Text format    


  246. RICARD L, Abisror N, Droin N, Selimoglu-Buet D, et al
    Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2018 Jan 25:1-3. doi: 10.1080/10428194.2018.1427857.
    PubMed     Text format    


  247. PANDEY G, Bakhshi S, Thakur B, Jain P, et al
    Prognostic significance of cathepsin L expression in pediatric acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jan 18:1-13. doi: 10.1080/10428194.2017.1422865.
    PubMed     Text format     Abstract available


  248. GUILLEM V, Calabuig M, Brunet S, Esteve J, et al
    Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.
    Leuk Lymphoma. 2018 Jan 18:1-11. doi: 10.1080/10428194.2017.1422858.
    PubMed     Text format     Abstract available


  249. LENNMYR EB, Kozlowski P, Ahlberg L, Bernell P, et al
    Real-world data on first relapse of acute lymphoblastic leukemia in patients >55 years.
    Leuk Lymphoma. 2018 Jan 18:1-4. doi: 10.1080/10428194.2017.1416369.
    PubMed     Text format    


  250. CAO L, Koh LP, Linn YC
    Successful treatment of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation with bortezomib.
    Leuk Lymphoma. 2018 Jan 18:1-3. doi: 10.1080/10428194.2017.1421759.
    PubMed     Text format    


  251. BODDU P, Kantarjian H, Ravandi F, Garcia-Manero G, et al
    Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jan 17:1-4. doi: 10.1080/10428194.2017.1422864.
    PubMed     Text format    


  252. CUI J, Zhu Z, Liu S, Li Q, et al
    Monitoring of leukemia stem cells in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2018 Jan 16:1-3. doi: 10.1080/10428194.2017.1421755.
    PubMed     Text format    


  253. YANG M, Xing S, Ou HL, Zhang L, et al
    Vibsanol A induces differentiation of acute myeloid leukemia cells via activation of the PKC signaling pathway and induction of ROS.
    Leuk Lymphoma. 2018 Jan 16:1-9. doi: 10.1080/10428194.2017.1421754.
    PubMed     Text format     Abstract available


  254. BLUME R, Rempel E, Manta L, Saeed BR, et al
    The molecular signature of AML with increased ALDH activity suggests a stem cell origin.
    Leuk Lymphoma. 2018 Jan 16:1-10. doi: 10.1080/10428194.2017.1422862.
    PubMed     Text format     Abstract available


  255. ZHOU H, Xu RZ, Gu Y, Shi PF, et al
    Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jan 15:1-13. doi: 10.1080/10428194.2017.1390229.
    PubMed     Text format     Abstract available


  256. SHAO H, Zeng Z, Cen J, Zhang J, et al
    The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.
    Leuk Lymphoma. 2018 Jan 15:1-7. doi: 10.1080/10428194.2017.1422860.
    PubMed     Text format     Abstract available


  257. COSIMATO V, Scalia G, Raia M, Gentile L, et al
    Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients.
    Leuk Lymphoma. 2018 Jan 15:1-4. doi: 10.1080/10428194.2017.1416366.
    PubMed     Text format    


  258. HANNON M, Wilde L, Nwaoduah N, Kasner M, et al
    Chronic myelomonocytic leukemia with central nervous system involvement.
    Leuk Lymphoma. 2018 Jan 11:1-2. doi: 10.1080/10428194.2017.1422866.
    PubMed     Text format    


  259. CRAMER P, Fraser G, Santucci-Silva R, Grosicki S, et al
    Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in t
    Leuk Lymphoma. 2018 Jan 3:1-10. doi: 10.1080/10428194.2017.1416364.
    PubMed     Text format     Abstract available


  260. RUAN J, Gao S, Yang J, Li H, et al
    WT1 protein is cleaved by caspase-3 in apoptotic leukemic cells.
    Leuk Lymphoma. 2018;59:162-170.
    PubMed     Text format     Abstract available


  261. GUO BB, Liang J, Allcock RJN, Mirzai B, et al
    A mutation in PTPN11 may drive leukemic transformation in a case of essential thrombocythemia.
    Leuk Lymphoma. 2018;59:245-248.
    PubMed     Text format    


  262. JANAKIRAM M, Verma A, Wang Y, Budhathoki A, et al
    Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease.
    Leuk Lymphoma. 2018;59:241-244.
    PubMed     Text format    


  263. ZHANG Y, Cheng Z, Yan WZ, Liu SF, et al
    Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes.
    Leuk Lymphoma. 2018;59:233-236.
    PubMed     Text format    


    December 2017
  264. HANIF A, Wang ES, Thompson JE, Baron JI, et al
    Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-3. doi: 10.1080/10428194.2017.1411595.
    PubMed     Text format    


  265. YABUSHITA T, Satake H, Maruoka H, Morita M, et al
    Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-8. doi: 10.1080/10428194.2017.1410888.
    PubMed     Text format     Abstract available


  266. GAY ND, Kozin E, Okada C, Danilov AV, et al
    Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-3. doi: 10.1080/10428194.2017.1410890.
    PubMed     Text format    


  267. HALDER A, Nayak KB, Chakraborty S
    Ecotopic viral integration site 1 (EVI1) transcriptionally targets talin1 (TLN1) and upregulates its expression in chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 7:1-3. doi: 10.1080/10428194.2017.1406089.
    PubMed     Text format    


  268. LI H, Zhang W, Kuang P, Ye Y, et al
    Combination of IKZF1 deletion and early molecular response show significant roles on prognostic stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
    Leuk Lymphoma. 2017 Dec 7:1-9. doi: 10.1080/10428194.2017.1406933.
    PubMed     Text format     Abstract available


  269. HERNANDEZ-GONZALEZ O, Ortiz-Zamudio JJ, Rodriguez-Pinal CJ, Alvarado-Morales I, et al
    Genetic polymorphisms of arylamine N-acetyltransferases 1 and 2 and the likelihood of developing pediatric acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Dec 7:1-8. doi: 10.1080/10428194.2017.1406090.
    PubMed     Text format     Abstract available


  270. LEI H, Wang W, Wu Y
    Targeting oncoproteins for degradation by small molecules in myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 4:1-8. doi: 10.1080/10428194.2017.1403600.
    PubMed     Text format     Abstract available


  271. GUPTA SK, Bakhshi S, Chopra A, Kamal VK, et al
    Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.
    Leuk Lymphoma. 2017 Dec 3:1-6. doi: 10.1080/10428194.2017.1408087.
    PubMed     Text format     Abstract available


  272. CHENG WY, Zhu YM, Cheng S, Chen YS, et al
    Development of B-cell prolymphocytic leukemia in a patient with splenic diffuse red pulp small B-cell lymphoma.
    Leuk Lymphoma. 2017 Dec 3:1-4. doi: 10.1080/10428194.2017.1405397.
    PubMed     Text format    



  273. XVII International Workshop on Chronic Lymphocytic Leukemia 2017 May 12--15, 2017, New York.
    Leuk Lymphoma. 2017;58.
    PubMed     Text format    


    November 2017
  274. RUGGIU M, Oberkampf F, Ghez D, Cony-Makhoul P, et al
    Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.
    Leuk Lymphoma. 2017 Nov 28:1-7. doi: 10.1080/10428194.2017.1397666.
    PubMed     Text format     Abstract available


  275. RIBERA JM, Morgades M, Montesinos P, Martino R, et al
    Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-10. doi: 10.1080/10428194.2017.1397661.
    PubMed     Text format     Abstract available


  276. KANNA R, Choudhary G, Ramachandra N, Steidl U, et al
    STAT3 inhibition as a therapeutic strategy for leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-7. doi: 10.1080/10428194.2017.1397668.
    PubMed     Text format     Abstract available


  277. PEI R, Si T, Lu Y, Zhou JX, et al
    Salvianolic acid A, a novel PI3K/Akt inhibitor, induces cell apoptosis and suppresses tumor growth in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-9. doi: 10.1080/10428194.2017.1399314.
    PubMed     Text format     Abstract available


  278. GOHIL SH, Maciocia N, Patrick P, Roberts T, et al
    LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-4. doi: 10.1080/10428194.2017.1399311.
    PubMed     Text format    


  279. PATNAIK MM
    The importance of FLT3 mutational analysis in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-14. doi: 10.1080/10428194.2017.1399312.
    PubMed     Text format     Abstract available


  280. SASAKI K, Mori Y, Yoshimoto G, Sakoda T, et al
    Successful treatment of Ph ALL with hematopoietic stem cell transplantation from the same HLA-haploidentical related donor of previous liver transplantation.
    Leuk Lymphoma. 2017 Nov 22:1-3. doi: 10.1080/10428194.2017.1403021.
    PubMed     Text format    


  281. AYED AO, Parikh SA
    Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
    Leuk Lymphoma. 2017 Nov 8:1-10. doi: 10.1080/10428194.2017.1397665.
    PubMed     Text format     Abstract available


  282. MARTINEZ-TRILLOS A, Pinyol M, Delgado J, Aymerich M, et al
    The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Nov 8:1-9. doi: 10.1080/10428194.2017.1397660.
    PubMed     Text format     Abstract available


  283. MCCURDY SR, Levis MJ
    Emerging molecular predictive and prognostic factors in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Nov 2:1-19. doi: 10.1080/10428194.2017.1393669.
    PubMed     Text format     Abstract available


    October 2017
  284. SATO R, Jacob J, Gaballa S
    Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Oct 30:1-4. doi: 10.1080/10428194.2017.1387907.
    PubMed     Text format    


  285. STEINBRECHER D, Jebaraj BMC, Schneider C, Edelmann J, et al
    Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.
    Leuk Lymphoma. 2017 Oct 24:1. doi: 10.1080/10428194.2017.1390236.
    PubMed     Text format     Abstract available


  286. YU J, Antic Z, van Reijmersdal SV, Hoischen A, et al
    Accurate detection of low-level mosaic mutations in pediatric acute lymphoblastic leukemia using single molecule tagging and deep-sequencing.
    Leuk Lymphoma. 2017 Oct 23:1-10. doi: 10.1080/10428194.2017.1390232.
    PubMed     Text format     Abstract available


  287. SALZER W, Bostrom B, Messinger Y, Perissinotti AJ, et al
    Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Oct 18:1-10. doi: 10.1080/10428194.2017.1386305.
    PubMed     Text format     Abstract available


  288. PENG L, Tang Y, Zhang Y, Guo S, et al
    Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia.
    Leuk Lymphoma. 2017 Oct 18:1-8. doi: 10.1080/10428194.2017.1387906.
    PubMed     Text format     Abstract available


  289. GEYER MB, Manjunath SH, Evans AG, Park JH, et al
    Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.
    Leuk Lymphoma. 2017 Oct 18:1-5. doi: 10.1080/10428194.2017.1390237.
    PubMed     Text format    


  290. LI WY, Wang Y, Chen SN, Qiu HY, et al
    Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1390235.
    PubMed     Text format     Abstract available


  291. MITSUI-SEKINAKA K, Sekinaka Y, Ogura Y, Honda M, et al
    A pediatric case of acute megakaryocytic leukemia with double chimeric transcripts of CBFA2T3-GLIS2 and DHH-RHEBL1.
    Leuk Lymphoma. 2017 Oct 18:1-3. doi: 10.1080/10428194.2017.1387901.
    PubMed     Text format    


  292. CORROCHER FA, Bueno de Paiva L, Duarte ASS, Ferro KP, et al
    Reduced expression of NR4A1 activates glycolytic pathway in acute promyelocytic leukemia cells.
    Leuk Lymphoma. 2017 Oct 17:1-4. doi: 10.1080/10428194.2017.1387900.
    PubMed     Text format    


  293. MOTOHASHI K, Fujisawa S, Doki N, Kobayashi T, et al
    Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2017 Oct 16:1-6. doi: 10.1080/10428194.2017.1387913.
    PubMed     Text format     Abstract available


  294. LEE LJ, Toze CL, Huang SJT, Gillan TL, et al
    Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.
    Leuk Lymphoma. 2017 Oct 16:1-8. doi: 10.1080/10428194.2017.1387904.
    PubMed     Text format     Abstract available


  295. ZHANG C, Amos Burke GA
    Pediatric precursor B-cell acute lymphoblastic leukemia with MYC 8q24 translocation - how to treat?
    Leuk Lymphoma. 2017 Oct 12:1-7. doi: 10.1080/10428194.2017.1387914.
    PubMed     Text format     Abstract available


  296. KATAGIRI S, Umezu T, Azuma K, Asano M, et al
    Hidden FLT3-D835Y clone in FLT3-ITD-positive acute myeloid leukemia that evolved into very late relapse with T-lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Oct 3:1-4. doi: 10.1080/10428194.2017.1382696.
    PubMed     Text format    


  297. VANGAPANDU HV, Chen H, Wierda WG, Keating MJ, et al
    Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells.
    Leuk Lymphoma. 2017 Oct 3:1-12. doi: 10.1080/10428194.2017.1376747.
    PubMed     Text format     Abstract available


    September 2017
  298. HOOGEVEEN PG, de Bie M, Noordijk R, Sonneveld E, et al
    Pitfalls in short-tandem repeat analysis as quality control for sample mix-up of pediatric acute lymphoblastic leukemia patients.
    Leuk Lymphoma. 2017 Sep 28:1-3. doi: 10.1080/10428194.2017.1382699.
    PubMed     Text format    


  299. APPLEBY N, O'Brien D, Quinn FM, Smyth L, et al
    Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-
    Leuk Lymphoma. 2017 Sep 19:1-10. doi: 10.1080/10428194.2017.1376746.
    PubMed     Text format     Abstract available


  300. ANDRITSOS LA, Grieselhuber NR, Anghelina M, Rogers KA, et al
    Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.
    Leuk Lymphoma. 2017 Sep 18:1-4. doi: 10.1080/10428194.2017.1365853.
    PubMed     Text format    


  301. KREINITZ N, Polliack A, Tadmor T
    Chronic lymphocytic leukemia is becoming more complex: how to define complex karyotype?
    Leuk Lymphoma. 2017 Sep 18:1-2. doi: 10.1080/10428194.2017.1376748.
    PubMed     Text format    


  302. RIZZOTTO L, Lai TH, Bottoni A, Woyach JA, et al
    Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia.
    Leuk Lymphoma. 2017 Sep 18:1-5. doi: 10.1080/10428194.2017.1376742.
    PubMed     Text format    


  303. VLIJM-KIEVIT A, Jorna NGE, Moll E, Pajkrt E, et al
    Acute lymphoblastic leukemia during the third trimester of pregnancy.
    Leuk Lymphoma. 2017 Sep 15:1-3. doi: 10.1080/10428194.2017.1375104.
    PubMed     Text format    


  304. MULANOVICH V, Kontoyiannis DP
    Acute myeloid leukemia and the infectious diseases consultant.
    Leuk Lymphoma. 2017 Sep 15:1-8. doi: 10.1080/10428194.2017.1365861.
    PubMed     Text format     Abstract available


  305. MESCHER C, Gilbertson D, Randall NM, Tarchand G, et al
    The impact of Agent Orange exposure on prognosis and management in patients with chronic lymphocytic leukemia: a National Veteran Affairs Tumor Registry Study.
    Leuk Lymphoma. 2017 Sep 14:1-8. doi: 10.1080/10428194.2017.1375109.
    PubMed     Text format     Abstract available


  306. VAUGHN JL, Kline D, Denlinger NM, Andritsos LA, et al
    Predictive performance of early warning scores in acute leukemia patients receiving induction chemotherapy.
    Leuk Lymphoma. 2017 Sep 13:1-3. doi: 10.1080/10428194.2017.1376744.
    PubMed     Text format    


  307. TAVARES M, Lemiale V, Mokart D, Pene F, et al
    Determinants of 1-year survival in critically ill acute leukemia patients: a GRRR-OH study.
    Leuk Lymphoma. 2017 Sep 13:1-9. doi: 10.1080/10428194.2017.1375106.
    PubMed     Text format     Abstract available


  308. PULA A, Stawiski K, Braun M, Iskierka-Jazdzewska E, et al
    Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.
    Leuk Lymphoma. 2017 Sep 11:1-11. doi: 10.1080/10428194.2017.1375101.
    PubMed     Text format     Abstract available


  309. PALLAVAJJALA A, Kim D, Li T, Ghiaur G, et al
    Genomic characterization of chromosome translocations in patients with T/myeloid mixed-phenotype acute leukemia.
    Leuk Lymphoma. 2017 Sep 7:1-8. doi: 10.1080/10428194.2017.1372577.
    PubMed     Text format     Abstract available


  310. SHUKLA A, Shukla V, Joshi SS
    Regulation of MAPK signaling and implications in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Sep 7:1-9. doi: 10.1080/10428194.2017.1370548.
    PubMed     Text format     Abstract available


  311. RODRIGUEZ CM, Stanganelli C, Bussi C, Arroyo D, et al
    Intracytoplasmic filamentous inclusions and IGHV rearrangements in a patient with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Sep 3:1-5. doi: 10.1080/10428194.2017.1370549.
    PubMed     Text format    


  312. GURBUXANI S
    The web of microRNA in B lymphoblastic leukemia.
    Leuk Lymphoma. 2017;58:2024-2025.
    PubMed     Text format    


    August 2017
  313. HUANG A, Huang C, Tang G, Cheng H, et al
    Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Aug 31:1-11. doi: 10.1080/10428194.2017.1369072.
    PubMed     Text format     Abstract available


  314. BURGSTALLER S, Stauder R, Kuehr T, Lang A, et al
    A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1.
    Leuk Lymphoma. 2017 Aug 30:1-6. doi: 10.1080/10428194.2017.1369070.
    PubMed     Text format     Abstract available


  315. CAO H, Xie J, Guo L, Han K, et al
    All-trans retinoic acid induces autophagic degradation of ubiquitin-like modifier activating enzyme 3 in acute promyelocytic leukemia cells.
    Leuk Lymphoma. 2017 Aug 29:1-9. doi: 10.1080/10428194.2017.1365850.
    PubMed     Text format     Abstract available


  316. BODDU P, Kantarjian H, Garcia-Manero G, Ravandi F, et al
    Time to response and survival in hypomethylating agent-treated acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 25:1-4. doi: 10.1080/10428194.2017.1365857.
    PubMed     Text format    


  317. FALANTES J, Pleyer L, Thepot S, Almeida AM, et al
    Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).
    Leuk Lymphoma. 2017 Aug 24:1-8. doi: 10.1080/10428194.2017.1365854.
    PubMed     Text format     Abstract available


  318. IACCARINO L, Ottone T, Hasan SK, Divona M, et al
    Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Leuk Lymphoma. 2017 Aug 24:1-3. doi: 10.1080/10428194.2017.1369067.
    PubMed     Text format    


  319. SI T, Lu Y, Li F, Jiang L, et al
    High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 24:1-7. doi: 10.1080/10428194.2017.1324157.
    PubMed     Text format     Abstract available



  320. Wendtner C-M, and Gregor M. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2017. http://dx.doi.org/10.1080/10428194.2017.1330474.
    Leuk Lymphoma. 2017 Aug 10:1. doi: 10.1080/10428194.2017.1363546.
    PubMed     Text format    


  321. CRUZ NM, Sugita M, Ewing-Crystal N, Lam L, et al
    Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 10:1-5. doi: 10.1080/10428194.2017.1361023.
    PubMed     Text format    


  322. JALBUT MM, Brunner AM, Amrein PC, Ballen KK, et al
    Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 9:1-4. doi: 10.1080/10428194.2017.1361028.
    PubMed     Text format    


  323. CHEN X, Dou H, Wang X, Huang Y, et al
    KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 9:1-8. doi: 10.1080/10428194.2017.1361025.
    PubMed     Text format     Abstract available


  324. CAYSSIALS E, Tartarin F, Guilhot J, Sorel N, et al
    Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors.
    Leuk Lymphoma. 2017 Aug 9:1-4. doi: 10.1080/10428194.2017.1357178.
    PubMed     Text format    


  325. DHERE V, Edelman S, Waller EK, Langston A, et al
    Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
    Leuk Lymphoma. 2017 Aug 7:1-7. doi: 10.1080/10428194.2017.1361027.
    PubMed     Text format     Abstract available


  326. KIVIOJA JL, Lopez Marti JM, Kumar A, Kontro M, et al
    Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 4:1-8. doi: 10.1080/10428194.2017.1357174.
    PubMed     Text format     Abstract available


  327. DIRSE V, Norvilas R, Gineikiene E, Matuzeviciene R, et al
    ETV6 and NOTCH1 germline variants in adult acute leukemia.
    Leuk Lymphoma. 2017 Aug 4:1-3. doi: 10.1080/10428194.2017.1359742.
    PubMed     Text format    


  328. SESE L, Rivaud E, Bron C, Leblond V, et al
    Unexpected Pneumocystis jirovecii pneumonia in patients with untreated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Aug 3:1-4. doi: 10.1080/10428194.2017.1357170.
    PubMed     Text format    


  329. MULCAHY A, Mulligan SP, Shumack SP
    Recommendations for skin cancer monitoring for patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Aug 3:1-5. doi: 10.1080/10428194.2017.1349903.
    PubMed     Text format    


  330. WANG A, Cai X, Qiang P, Duan Q, et al
    Successful treatment of a patient with acute promyelocytic leukemia with a STAT5B/RARA fusion gene using decitabine.
    Leuk Lymphoma. 2017 Aug 1:1-3. doi: 10.1080/10428194.2017.1357176.
    PubMed     Text format    


    July 2017
  331. YANADA M, Mori J, Aoki J, Harada K, et al
    Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients.
    Leuk Lymphoma. 2017 Jul 28:1-9. doi: 10.1080/10428194.2017.1357173.
    PubMed     Text format     Abstract available


  332. GEYER MB, Tallman MS
    Digging deeper in relapsed acute lymphoblastic leukemia: impact of MRD status on outcome in second remission.
    Leuk Lymphoma. 2017 Jul 28:1-3. doi: 10.1080/10428194.2017.1355971.
    PubMed     Text format    


  333. KONG J, Zhao XS, Qin YZ, Zhu HH, et al
    The initial level of MLL-partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 26:1-6. doi: 10.1080/10428194.2017.1352091.
    PubMed     Text format     Abstract available


  334. ALDOSS I, Stein AS
    Advances in adult acute lymphoblastic leukemia therapy.
    Leuk Lymphoma. 2017 Jul 26:1-18. doi: 10.1080/10428194.2017.1354372.
    PubMed     Text format     Abstract available


  335. STRICKLER N, Balabanov S, Casauro K, Schanz U, et al
    Acute central nervous system complications and ammonium levels in adult patients with acute lymphoblastic leukemia receiving l-asparaginase.
    Leuk Lymphoma. 2017 Jul 21:1-8. doi: 10.1080/10428194.2017.1352090.
    PubMed     Text format     Abstract available


  336. GONZALEZ-GASCON Y MARIN I, Hernandez-Sanchez M, Rodriguez-Vicente AE, Puiggros A, et al
    Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jul 21:1-10. doi: 10.1080/10428194.2017.1349901.
    PubMed     Text format     Abstract available


  337. ENGLAND JT, Leitch HA
    Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.
    Leuk Lymphoma. 2017 Jul 21:1-3. doi: 10.1080/10428194.2017.1349904.
    PubMed     Text format    


  338. SHLIAKHTSITSAVA K, Romero SAD, Dewald SR, Su HI, et al
    Pregnancy and child health outcomes in pediatric and young adult leukemia and lymphoma survivors: a systematic review.
    Leuk Lymphoma. 2017 Jul 21:1-17. doi: 10.1080/10428194.2017.1352097.
    PubMed     Text format     Abstract available


  339. ALLAN JN, Roboz GJ, Askin G, Ritchie E, et al
    CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.
    Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1352089.
    PubMed     Text format     Abstract available


  340. SHORT NJ, Kantarjian H, Ravandi F, Huang X, et al
    A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1349907.
    PubMed     Text format     Abstract available


  341. RAUSCH CR, Marini BL, Benitez LL, Elias A, et al
    PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia dagger.
    Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1349902.
    PubMed     Text format     Abstract available


  342. AMMANN EM, Shanafelt TD, Wright KB, McDowell BD, et al
    Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length.
    Leuk Lymphoma. 2017 Jul 18:1-7. doi: 10.1080/10428194.2017.1349905.
    PubMed     Text format     Abstract available


  343. HOROWITZ NA, Henig I, Henig O, Benyamini N, et al
    Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis.
    Leuk Lymphoma. 2017 Jul 13:1-7. doi: 10.1080/10428194.2017.1347651.
    PubMed     Text format     Abstract available


  344. CHELYSHEVA E, Turkina A, Polushkina E, Shmakov R, et al
    Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment.
    Leuk Lymphoma. 2017 Jul 13:1-6. doi: 10.1080/10428194.2017.1347929.
    PubMed     Text format     Abstract available


  345. WILLIAMS AM, Baran AM, Meacham PJ, Feldman MM, et al
    Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.
    Leuk Lymphoma. 2017 Jul 11:1-8. doi: 10.1080/10428194.2017.1347931.
    PubMed     Text format     Abstract available


  346. KREMER B, Tsai DE, Debonera F, Cohen PL, et al
    Spontaneous remission of acute myeloid leukemia after discontinuation of lenalidomide.
    Leuk Lymphoma. 2017 Jul 11:1-3. doi: 10.1080/10428194.2017.1347652.
    PubMed     Text format    


  347. GARRISI VM, Sgherza N, Breccia M, Iacobazzi A, et al
    Association between proteomic profile and molecular response in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2017 Jul 11:1-3. doi: 10.1080/10428194.2017.1344841.
    PubMed     Text format    


  348. DAMLAJ M, Al Balwi M, Al Mugairi AM
    Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations.
    Leuk Lymphoma. 2017 Jul 11:1-4. doi: 10.1080/10428194.2017.1347653.
    PubMed     Text format    


  349. SAYGIN C, Papadantonakis N, Cassaday RD, Liedtke M, et al
    Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.
    Leuk Lymphoma. 2017 Jul 11:1-9. doi: 10.1080/10428194.2017.1344842.
    PubMed     Text format     Abstract available


  350. CALVELLO C, Rocca B, Klersy C, Zappatore R, et al
    Alternative splicing of hTERT: a further mechanism for the control of active hTERT in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-8. doi: 10.1080/10428194.2017.1346252.
    PubMed     Text format     Abstract available


  351. SALMOIRAGHI S, Rambaldi A, Spinelli O
    TP53 in adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-12. doi: 10.1080/10428194.2017.1344839.
    PubMed     Text format     Abstract available


  352. XU W, Li X, Quan L, Yao J, et al
    Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-10. doi: 10.1080/10428194.2017.1346253.
    PubMed     Text format     Abstract available


  353. HAMPRAS SS, Locke FL, Chavez JC, Patel NS, et al
    Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients.
    Leuk Lymphoma. 2017 Jul 6:1-7. doi: 10.1080/10428194.2017.1342822.
    PubMed     Text format     Abstract available


  354. XU L, Zhang M, Li H, Guan W, et al
    SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-13. doi: 10.1080/10428194.2017.1344843.
    PubMed     Text format     Abstract available


    June 2017
  355. KATKISH LA, Rangaraju S, Rector TS, Gravely AA, et al
    Incidence of unprovoked venous thromboembolic events in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 27:1-3. doi: 10.1080/10428194.2017.1341979.
    PubMed     Text format    


  356. SANDOVAL-SUS JD, Chavez JC, Dalia S, Naqvi SMH, et al
    Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 22:1-10. doi: 10.1080/10428194.2017.1323271.
    PubMed     Text format     Abstract available


  357. BORUTINSKAITE V, Virksaite A, Gudelyte G, Navakauskiene R, et al
    Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells.
    Leuk Lymphoma. 2017 Jun 22:1-10. doi: 10.1080/10428194.2017.1339881.
    PubMed     Text format     Abstract available


  358. MAFFEI R, Fiorcari S, Martinelli S, Benatti S, et al
    Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
    Leuk Lymphoma. 2017 Jun 22:1-11. doi: 10.1080/10428194.2017.1339872.
    PubMed     Text format     Abstract available


  359. SANIKOMMU SR, Clemente MJ, Chomczynski P, Afable MG 2nd, et al
    Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL).
    Leuk Lymphoma. 2017 Jun 20:1-7. doi: 10.1080/10428194.2017.1339880.
    PubMed     Text format     Abstract available


  360. VILLEMAGNE SANCHEZ LA, O'Callaghan C, Gough K, Hall K, et al
    Patient perceptions of treatment-free remission in chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 15:1-10. doi: 10.1080/10428194.2017.1337114.
    PubMed     Text format     Abstract available


  361. KANSAGRA A, Dahiya S, Litzow M
    Continuing challenges and current issues in acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Jun 11:1-16. doi: 10.1080/10428194.2017.1335397.
    PubMed     Text format     Abstract available


  362. FARSHCHI ZARABI S, Chan S, Gupta V, Khalaf D, et al
    Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived.
    Leuk Lymphoma. 2017 Jun 9:1-4. doi: 10.1080/10428194.2017.1323273.
    PubMed     Text format    


  363. DROIN N, Lucas N, Parinet V, Selimoglu-Buet D, et al
    Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients.
    Leuk Lymphoma. 2017 Jun 8:1-5. doi: 10.1080/10428194.2017.1330468.
    PubMed     Text format     Abstract available


  364. LARSEN CM, Villarraga HR, Begna KH, Litzow MR, et al
    Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 8:1-4. doi: 10.1080/10428194.2017.1323268.
    PubMed     Text format    


  365. TIONG IS, Tan P, McManus J, Cummings N, et al
    Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 8:1-4. doi: 10.1080/10428194.2017.1334122.
    PubMed     Text format    


  366. NASILLO V, Paolini A, Riva G, Morselli M, et al
    Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study.
    Leuk Lymphoma. 2017 Jun 7:1-4. doi: 10.1080/10428194.2017.1321748.
    PubMed     Text format    


  367. MEGIAS-VERICAT JE, Montesinos P, Herrero MJ, Moscardo F, et al
    Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
    Leuk Lymphoma. 2017 Jun 2:1-15. doi: 10.1080/10428194.2017.1323267.
    PubMed     Text format     Abstract available


  368. BHATT VR, Gundabolu K, Koll T, Maness LJ, et al
    Initial therapy for acute myeloid leukemia in older patients: principles of care.
    Leuk Lymphoma. 2017 Jun 2:1-13. doi: 10.1080/10428194.2017.1323275.
    PubMed     Text format     Abstract available


  369. SOLE C, Martinez D, Gine E, Gonzalez-Farre B, et al
    Expression of a truncated B lymphocyte-induced maturation protein-1 isoform is associated with an incomplete plasmacytic differentiation program in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 2:1-4. doi: 10.1080/10428194.2017.1330470.
    PubMed     Text format    


  370. NGUYEN D, Haley L, Pallavajjala A, Gojo I, et al
    Identification of a novel KMT2A-SEPT14 fusion in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 2:1-3. doi: 10.1080/10428194.2017.1324163.
    PubMed     Text format    


  371. WEBSTER JA, Pratz KW
    Acute myeloid leukemia in the elderly: therapeutic options and choice.
    Leuk Lymphoma. 2017 Jun 2:1-14. doi: 10.1080/10428194.2017.1330956.
    PubMed     Text format     Abstract available


  372. WENDTNER CM, Gregor M
    Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 1:1-11. doi: 10.1080/10428194.2017.1330474.
    PubMed     Text format     Abstract available


  373. PIGGIN A, Bayly E, Tam CS
    Novel agents versus chemotherapy as frontline treatment of CLL.
    Leuk Lymphoma. 2017;58:1320-1324.
    PubMed     Text format     Abstract available


    May 2017
  374. GAFTER-GVILI A
    G6PD deficiency and fungal infections in patients with acute myeloid leukemia: less enzyme more fungus.
    Leuk Lymphoma. 2017 May 31:1-2. doi: 10.1080/10428194.2017.1330478.
    PubMed     Text format    


  375. MOTLLO C, Ribera JM, Morgades M, Granada I, et al
    Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 May 30:1-9. doi: 10.1080/10428194.2017.1326596.
    PubMed     Text format     Abstract available


  376. LEE SE, Choi SY, Kim SH, Song HY, et al
    Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.
    Leuk Lymphoma. 2017 May 25:1-9. doi: 10.1080/10428194.2017.1320711.
    PubMed     Text format     Abstract available


  377. SAINI L, Brandwein J, Szkotak A, Ghosh S, et al
    Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 25:1-8. doi: 10.1080/10428194.2017.1326032.
    PubMed     Text format     Abstract available


  378. XU X, Nagel S, Quentmeier H, Wang Z, et al
    KDM3B shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 25:1-10. doi: 10.1080/10428194.2017.1324156.
    PubMed     Text format     Abstract available


  379. HOSHINO T, Taki T, Takada S, Hatsumi N, et al
    Spontaneous remission of adult acute myeloid leukemia with t(8;16)(p11;p13)/MOZ-CBP fusion.
    Leuk Lymphoma. 2017 May 23:1-3. doi: 10.1080/10428194.2017.1320712.
    PubMed     Text format    


  380. BRECCIA M, Efficace F
    Are chronic myeloid leukemia patients ready to stop long-term treatment?
    Leuk Lymphoma. 2017 May 23:1-3. doi: 10.1080/10428194.2017.1330476.
    PubMed     Text format    


  381. LARSON RA
    Managing CNS disease in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 May 23:1-11. doi: 10.1080/10428194.2017.1326597.
    PubMed     Text format     Abstract available


  382. BUTTNER B, Knoth H, Kramer M, Oertel R, et al
    Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 16:1-10. doi: 10.1080/10428194.2017.1319051.
    PubMed     Text format     Abstract available


  383. TANOUE S, Konuma T, Takahashi S, Watanabe E, et al
    Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome.
    Leuk Lymphoma. 2017 May 16:1-3. doi: 10.1080/10428194.2017.1318440.
    PubMed     Text format    


  384. CAMPREGHER PV, Halley NDS, Vieira GA, Fernandes JF, et al
    Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.
    Leuk Lymphoma. 2017 May 16:1-4. doi: 10.1080/10428194.2017.1318437.
    PubMed     Text format    


  385. OWEN C, Christofides A, Johnson N, Lawrence T, et al
    Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 May 16:1-9. doi: 10.1080/10428194.2017.1318439.
    PubMed     Text format     Abstract available


  386. BUSCA A, Lessi F, Verga L, Candoni A, et al
    SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
    Leuk Lymphoma. 2017 May 16:1-6. doi: 10.1080/10428194.2017.1318438.
    PubMed     Text format     Abstract available


  387. OKABE S, Tauchi T, Tanaka Y, Ohyashiki K, et al
    Targeting peroxisome proliferator-activated receptors: a novel strategy for Philadelphia chromosome-positive leukemia cells.
    Leuk Lymphoma. 2017 May 15:1-3. doi: 10.1080/10428194.2017.1312373.
    PubMed     Text format    


  388. ZHAO B, Bhattacharya S, Yu Q, Fuchs SY, et al
    Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.
    Leuk Lymphoma. 2017 May 15:1-7. doi: 10.1080/10428194.2017.1319053.
    PubMed     Text format     Abstract available


  389. SHANMUGANATHAN N, Hiwase DK, Ross DM
    Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.
    Leuk Lymphoma. 2017 May 9:1-12. doi: 10.1080/10428194.2017.1312377.
    PubMed     Text format     Abstract available


  390. AW A, Brown JR
    The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 May 9:1-11. doi: 10.1080/10428194.2017.1312387.
    PubMed     Text format     Abstract available


  391. COLOMER-LAHIGUERA S, Pisecker M, Konig M, Nebral K, et al
    MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.
    Leuk Lymphoma. 2017 May 9:1-10. doi: 10.1080/10428194.2017.1312383.
    PubMed     Text format     Abstract available


    April 2017
  392. LIU H, Zhang J, Ren S, Chen M, et al
    Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china.
    Leuk Lymphoma. 2017 Apr 13:1-4. doi: 10.1080/10428194.2017.1312378.
    PubMed     Text format    


  393. DRENNAN AC, Rui L
    HiJAKing the epigenome in leukemia and lymphoma.
    Leuk Lymphoma. 2017 Apr 12:1-8. doi: 10.1080/10428194.2017.1312370.
    PubMed     Text format     Abstract available


  394. SANNA M, Caocci G, Ledda A, Orru F, et al
    Glucose-6-phosphate dehydrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2017 Apr 12:1-10. doi: 10.1080/10428194.2017.1312666.
    PubMed     Text format     Abstract available


  395. BOSCH R, Mora A, Vicente EP, Ferrer G, et al
    FcgammaRIIb expression in early stage chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Apr 4:1-7. doi: 10.1080/10428194.2017.1307981.
    PubMed     Text format     Abstract available


  396. WASHIO K, Oka T, Abdalkader L, Muraoka M, et al
    Gene expression analysis of hypersensitivity to mosquito bite, chronic active EBV infection and NK/T-lymphoma/leukemia.
    Leuk Lymphoma. 2017 Apr 3:1-12. doi: 10.1080/10428194.2017.1304762.
    PubMed     Text format     Abstract available


  397. HARIVENKATESH N, Kumar L, Bakhshi S, Sharma A, et al
    Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Leuk Lymphoma. 2017 Apr 3:1-9. doi: 10.1080/10428194.2017.1287359.
    PubMed     Text format     Abstract available


  398. ROBESOVA B, Jeziskova I, Krejci M, Mayer J, et al
    Genesis of new allele at locus D2S1360 in leukemia patient.
    Leuk Lymphoma. 2017 Apr 3:1-4. doi: 10.1080/10428194.2017.1307363.
    PubMed     Text format    


  399. BEAUPIN LK, Bostrom B, Barth MJ, Franklin I, et al
    Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review.
    Leuk Lymphoma. 2017;58:766-772.
    PubMed     Text format     Abstract available


    March 2017
  400. RAFELSON WM, Reagan JL, Fast LD, Lim SH, et al
    Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?
    Leuk Lymphoma. 2017 Mar 28:1-9. doi: 10.1080/10428194.2017.1306646.
    PubMed     Text format     Abstract available


  401. CHEN X, Othus M, Wood BL, Walter RB, et al
    Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Mar 28:1-3. doi: 10.1080/10428194.2017.1307359.
    PubMed     Text format    


  402. HEISEL RW, Sutton RR, Mascara GP, Winger DG, et al
    Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine.
    Leuk Lymphoma. 2017 Mar 28:1-8. doi: 10.1080/10428194.2017.1306645.
    PubMed     Text format     Abstract available


    January 2016
  403. GRYGOROWICZ MA, Biernacka M, Bujko M, Nowak E, et al
    Human regulatory T cells suppress proliferation of B lymphoma cells.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: